Tevogen Bio Holdings (TVGN) Research & Development (2023 - 2026)

Tevogen Bio Holdings has reported Research & Development for 4 years, with the latest figure at $3.1 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 1.89% year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2026 stood at $11.1 million (down 17.63% YoY), and the FY2025 full-year result was $11.1 million, down 64.19% from the prior year.
• Research & Development for Q1 2026 stood at $3.1 million, up from $2.1 million in the prior quarter.
• The five-year high for Research & Development was $20.8 million in Q1 2024, with the low at $908049.0 in Q4 2023.
• Historically, Research & Development has averaged $3.8 million across 4 years, with a median of $2.8 million in 2024.
• Annual changes were most pronounced in 2024 — Research & Development soared 1444.83% — and 2025, when it slumped 84.65%.
• Tevogen Bio Holdings' Research & Development stood at $908049.0 in 2023, then surged by 212.35% to $2.8 million in 2024, then retreated by 25.76% to $2.1 million in 2025, then jumped by 48.87% to $3.1 million in 2026.
• The last three Research & Development figures came in at $3.1 million (Q1 2026), $2.1 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.